Two months after a key FDA panel voted down Merck’s conditional nod for Keytruda as a third-line treatment for certain stomach cancer patients, the company says it’s pulling the plug on the indication. Following consultation with the FDA, Merck on Thursday said it will voluntarily withdraw its U.S. accelerated approval for Keytruda as a third-line… Read More »
Merck announced Thursday it will end the development of its experimental drug for patients hospitalized with severe Covid-19 after the Food and Drug Administration asked the company to provide additional data to support an emergency use authorization. New Jersey-based Merck acquired the drug, MK-7110, through its $ 425 million acquisition of privately held biopharmaceutical company… Read More »
CHICAGO (Reuters) – Merck & Co Inc (MRK.N), which has largely kept to the sidelines of the race for COVID-19 treatments, said it was buying Austrian vaccine maker Themis Bioscience and would collaborate with research nonprofit IAVI to develop two separate vaccines. It also announced a partnership with privately held Ridgeback Biotherapeutics to develop an… Read More »
As detailed in The Highwire video above, in January 2020, Dr. Julie Gerberding — director of the U.S. Centers for Disease Control and Prevention from 2002 until 2009, who after leaving the CDC became president of Merck’s vaccine division in January 20101 — sold half her Merck stock options for $ 9.11 million. Gerberding also… Read More »